Arteriovenous Fistula Pipeline The therapeutic pipeline for AV fistula creation and maintenance is rapidly evolving, driven by rising ESRD cases and limitations of current surgical methods. Despite being the preferred access for hemodialysis, AV fistulas face issues like maturation failure … Continue reading →

Chronic Rhinosinusitis Pipeline The therapeutic pipeline for chronic rhinosinusitis (CRS) is shifting toward targeted biologics, oral small molecules, and advanced delivery systems to address its complex inflammation. Standard treatments offer only temporary relief, with frequent recurrence—especially in CRSwNP patients—driving demand … Continue reading →

Chronic Periodontitis Pipeline The therapeutic pipeline for chronic periodontitis is advancing, with growing interest in regenerative medicine, host-modulation, and novel antimicrobials. Current treatments can slow progression but rarely reverse tissue loss or fully eliminate biofilms, highlighting the need for therapies … Continue reading →

Angioimmunoblastic T-Cell Lymphoma Pipeline The therapeutic pipeline for angioimmunoblastic T-cell lymphoma (AITL) is growing, driven by the need to address its aggressive nature and poor prognosis. Current treatments, such as CHOP-like chemotherapy and stem cell transplants, often result in high … Continue reading →

Erosive Esophagitis Pipeline The treatment of erosive esophagitis (EE), a severe form of GERD causing esophageal damage, is evolving beyond proton pump inhibitors (PPIs). Despite PPIs being the standard therapy, issues like incomplete healing, symptom recurrence, and PPI resistance highlight … Continue reading →

Macular Telangiectasia (MacTel) Pipeline Insight The MacTel treatment landscape is advancing, fueled by research into neurodegeneration, vascular issues, and metabolic dysfunction. Type 2 MacTel, the most common form, remains the focus, as current care is mainly supportive. Improved understanding of … Continue reading →